Can a new pill protect kidneys from IgA nephropathy?

NCT ID NCT06137768

Completed Disease control Sponsor: Chengdu Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests an experimental drug called HRS-5965 in people with primary IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug can reduce protein leakage in the urine, a sign of kidney damage. About 123 adults with confirmed IgA nephropathy will receive either HRS-5965 or a placebo to compare effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called HRS-5965
What this could lead to: If successful, HRS-5965 could offer a new treatment option to slow kidney damage in people with IgA nephropathy.
What could go wrong: This is an early-phase trial with a small number of participants, so the drug may not prove effective or safe. Side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IGA NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY IGA NEPHROPATHY

Contacts and locations

Show contact details

Locations

Beijing University First Hospital

Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.